Clinical data | |
---|---|
Trade names | Lexotan, Lexotanil, others |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Addiction liability | High[1] |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 84% |
Protein binding | 70% |
Metabolism | Liver: P450 |
Metabolites | 3-hydroxybromazepam |
Elimination half-life | 12–20 hours (avg. 17hr)[3] |
Excretion | Urine 69%, as metabolites[1] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.015.748 |
Chemical and physical data | |
Formula | C14H10BrN3O |
Molar mass | 316.158 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Bromazepam, sold under many brand names, is a benzodiazepine. It is mainly an anti-anxiety agent with similar side effects to diazepam. In addition to being used to treat anxiety or panic states, bromazepam may be used as a premedicant prior to minor surgery. Bromazepam typically comes in doses of 3 mg and 6 mg tablets.[4]
It was patented in 1961 by Roche and approved for medical use in 1974.[5]